J&J, Legend win FDA nod for cell therapy challenger to BMS in multiple myeloma March 1, 2022 Auto Bot BioPharma, CAR-T, cell therapy, Clinical Trials, FDA, Johnson & Johnson, Legal, multiple myeloma, Pharma 0 Approval of the Johnson & Johnson and Legend Biotech cell therapy, Carvykti, marks the second CAR T-cell therapy to clear the regulatory bar for multiple myeloma. The FDA approved Bristol Myers Squibb’s cell therapy Abecma last year.